Effect of atorvastatin and rosuvasta tin on the fatty acid spectrum of lymphocyte membranes in patients with unstable angina

Numerous studies have demonstrated the superiority of rosuvastatin over other statins in the treatment of cardiovascular disease. It has been proven that rosuvastatin is more effectively lowers low-density lipoprotein cholesterol in patients with cardiovascular disease than other members of this drug group. Despite the known mechanisms of action of statins on blood lipids, their effective use in patients with cardiovascular disease, as well as side effects, the influence of these drugs on the fatty acid spectrum of lymphocyte (LC) membrane phospholipids in patients with ischemic heart disease remains unexplored. The results of the studies cited in the article indicate that, in patients with unstable angina who received the therapy that included rosuvastatin, unlike patients receiving the basic treatment with atorvastatin, the relative phosphate lipid contents of palmitic, stearic, and stearin arachidonic polyunsaturated fatty acids and the amount of unsaturated fatty acids are normalized, which testifies to the stabilization of membranes as dynamic structures.

Cytological Preservation Using 1,5-Difluro 2, 4-Dinitrobenzene

A protein cross-linking agent, 1,5-difluro 2,4-dinitrobenzene (DFF) has been used for the preservation of red blood cells, liver and cartilage. This difluro compound is known for Its cross-linking ability which results in the stabilization of membranes by reacting with the free amino groups; this removes the positive charge by removal of a hydrogen atom. The double site on the difluro compound can react if the two amino groups are 5Å or more apart. It also reacts with sulfhydryl, tyrosyl or histidyl groups to form stable dinitro phenyl derivatives. The present studies indicate that preservation extends into the ultrastructure level and demonstrates a method for holding biological material for prolonged periods.